New G-CSF agonists for neutropenia therapy

Jonathan Hoggatt, Louis Pelus

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Introduction: Granulocyte colony-stimulating factor (G-CSF; filgrastim) and its pegylated form (pegfilgrastim) are widely used to treat neutropenia associated with myelosuppressive chemotherapy and bone marrow transplantation, AIDS-associated or drug-induced neutropenia, and neutropenic diseases. G-CSF facilitates restoration of neutrophil counts, decreases incidence of infection/febrile neutropenia and reduces resource utilization. G-CSF is also widely used to mobilize peripheral blood stem cells for hematopoietic transplant. Areas covered: We review the therapeutic use, cost effectiveness and disease impact of G-CSF for neutropenia, development of G-CSF biosimilars and current next-generation discovery efforts. Expert opinion: G-CSF has impacted the treatment and survival of patients with congenital neutropenias. For chemotherapy-associated neutropenia, cost effectiveness and impact on survival are still unclear. G-CSFs are expensive and require systemic administration. Market entry of new biosimilars, some with enhanced half-life profiles, will probably reduce cost and increase cost effectiveness. There is no evidence that marketed or late development biosimilars display effectiveness superior to current G-CSFs. Second-generation compounds that mimic the activity of G-CSF at its receptor, induce endogenous ligand(s) or offer adjunct activity have been reported and represent attractive G-CSF alternatives, but are in preclinical stages. A significant therapeutic advance will require reduced depth and duration of neutropenia compared to current G-CSFs.

Original languageEnglish
Pages (from-to)21-35
Number of pages15
JournalExpert Opinion on Investigational Drugs
Volume23
Issue number1
DOIs
StatePublished - Jan 2014

Fingerprint

Granulocyte Colony-Stimulating Factor
Neutropenia
Biosimilar Pharmaceuticals
Therapeutics
Cost-Benefit Analysis
Drug Therapy
Febrile Neutropenia
Cost of Illness
Survival
Expert Testimony
Therapeutic Uses
Bone Marrow Transplantation
Half-Life
Acquired Immunodeficiency Syndrome
Neutrophils
Ligands
Transplants
Costs and Cost Analysis

Keywords

  • Filgrastim
  • G-CSF
  • G-CSF agonists
  • Neutropenia
  • Pegfilgrastim

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

New G-CSF agonists for neutropenia therapy. / Hoggatt, Jonathan; Pelus, Louis.

In: Expert Opinion on Investigational Drugs, Vol. 23, No. 1, 01.2014, p. 21-35.

Research output: Contribution to journalArticle

Hoggatt, Jonathan ; Pelus, Louis. / New G-CSF agonists for neutropenia therapy. In: Expert Opinion on Investigational Drugs. 2014 ; Vol. 23, No. 1. pp. 21-35.
@article{8c70f6b728f44e92b92a3f9d61df0815,
title = "New G-CSF agonists for neutropenia therapy",
abstract = "Introduction: Granulocyte colony-stimulating factor (G-CSF; filgrastim) and its pegylated form (pegfilgrastim) are widely used to treat neutropenia associated with myelosuppressive chemotherapy and bone marrow transplantation, AIDS-associated or drug-induced neutropenia, and neutropenic diseases. G-CSF facilitates restoration of neutrophil counts, decreases incidence of infection/febrile neutropenia and reduces resource utilization. G-CSF is also widely used to mobilize peripheral blood stem cells for hematopoietic transplant. Areas covered: We review the therapeutic use, cost effectiveness and disease impact of G-CSF for neutropenia, development of G-CSF biosimilars and current next-generation discovery efforts. Expert opinion: G-CSF has impacted the treatment and survival of patients with congenital neutropenias. For chemotherapy-associated neutropenia, cost effectiveness and impact on survival are still unclear. G-CSFs are expensive and require systemic administration. Market entry of new biosimilars, some with enhanced half-life profiles, will probably reduce cost and increase cost effectiveness. There is no evidence that marketed or late development biosimilars display effectiveness superior to current G-CSFs. Second-generation compounds that mimic the activity of G-CSF at its receptor, induce endogenous ligand(s) or offer adjunct activity have been reported and represent attractive G-CSF alternatives, but are in preclinical stages. A significant therapeutic advance will require reduced depth and duration of neutropenia compared to current G-CSFs.",
keywords = "Filgrastim, G-CSF, G-CSF agonists, Neutropenia, Pegfilgrastim",
author = "Jonathan Hoggatt and Louis Pelus",
year = "2014",
month = "1",
doi = "10.1517/13543784.2013.838558",
language = "English",
volume = "23",
pages = "21--35",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - New G-CSF agonists for neutropenia therapy

AU - Hoggatt, Jonathan

AU - Pelus, Louis

PY - 2014/1

Y1 - 2014/1

N2 - Introduction: Granulocyte colony-stimulating factor (G-CSF; filgrastim) and its pegylated form (pegfilgrastim) are widely used to treat neutropenia associated with myelosuppressive chemotherapy and bone marrow transplantation, AIDS-associated or drug-induced neutropenia, and neutropenic diseases. G-CSF facilitates restoration of neutrophil counts, decreases incidence of infection/febrile neutropenia and reduces resource utilization. G-CSF is also widely used to mobilize peripheral blood stem cells for hematopoietic transplant. Areas covered: We review the therapeutic use, cost effectiveness and disease impact of G-CSF for neutropenia, development of G-CSF biosimilars and current next-generation discovery efforts. Expert opinion: G-CSF has impacted the treatment and survival of patients with congenital neutropenias. For chemotherapy-associated neutropenia, cost effectiveness and impact on survival are still unclear. G-CSFs are expensive and require systemic administration. Market entry of new biosimilars, some with enhanced half-life profiles, will probably reduce cost and increase cost effectiveness. There is no evidence that marketed or late development biosimilars display effectiveness superior to current G-CSFs. Second-generation compounds that mimic the activity of G-CSF at its receptor, induce endogenous ligand(s) or offer adjunct activity have been reported and represent attractive G-CSF alternatives, but are in preclinical stages. A significant therapeutic advance will require reduced depth and duration of neutropenia compared to current G-CSFs.

AB - Introduction: Granulocyte colony-stimulating factor (G-CSF; filgrastim) and its pegylated form (pegfilgrastim) are widely used to treat neutropenia associated with myelosuppressive chemotherapy and bone marrow transplantation, AIDS-associated or drug-induced neutropenia, and neutropenic diseases. G-CSF facilitates restoration of neutrophil counts, decreases incidence of infection/febrile neutropenia and reduces resource utilization. G-CSF is also widely used to mobilize peripheral blood stem cells for hematopoietic transplant. Areas covered: We review the therapeutic use, cost effectiveness and disease impact of G-CSF for neutropenia, development of G-CSF biosimilars and current next-generation discovery efforts. Expert opinion: G-CSF has impacted the treatment and survival of patients with congenital neutropenias. For chemotherapy-associated neutropenia, cost effectiveness and impact on survival are still unclear. G-CSFs are expensive and require systemic administration. Market entry of new biosimilars, some with enhanced half-life profiles, will probably reduce cost and increase cost effectiveness. There is no evidence that marketed or late development biosimilars display effectiveness superior to current G-CSFs. Second-generation compounds that mimic the activity of G-CSF at its receptor, induce endogenous ligand(s) or offer adjunct activity have been reported and represent attractive G-CSF alternatives, but are in preclinical stages. A significant therapeutic advance will require reduced depth and duration of neutropenia compared to current G-CSFs.

KW - Filgrastim

KW - G-CSF

KW - G-CSF agonists

KW - Neutropenia

KW - Pegfilgrastim

UR - http://www.scopus.com/inward/record.url?scp=84889783832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889783832&partnerID=8YFLogxK

U2 - 10.1517/13543784.2013.838558

DO - 10.1517/13543784.2013.838558

M3 - Article

C2 - 24073859

AN - SCOPUS:84889783832

VL - 23

SP - 21

EP - 35

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 1

ER -